托格列净

更新时间：2024-01-01 23:06:51

托格列净结构式	常用名	托格列净	英文名	Tofogliflozin (hydrate)
	CAS号	1201913-82-7	分子量	404.45400
	密度	N/A	沸点	N/A
	分子式	C₂₂H₂₈O₇	熔点	N/A
	MSDS	N/A	闪点	N/A

托格列净用途

Tofogliflozin(CSG-452)是SGLT2高效选择性抑制剂,对人源、大鼠和小鼠SGLT2的Ki值分别为2.9、14.9和6.4nM。

中文名	托格列净
英文名	(3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol,hydrate
英文别名	更多

描述	Tofogliflozin(CSG-452)是SGLT2高效选择性抑制剂,对人源、大鼠和小鼠SGLT2的Ki值分别为2.9、14.9和6.4nM。
相关类别	信号通路 >> 跨膜转运 >> SGLT 研究领域 >> 代谢疾病
参考文献	[1]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. [2]. Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 Oct;170(3):519-31. [3]. Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobioti [4]. Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23.

描述

Tofogliflozin(CSG-452)是SGLT2高效选择性抑制剂,对人源、大鼠和小鼠SGLT2的Ki值分别为2.9、14.9和6.4nM。

相关类别

信号通路 >> 跨膜转运 >> SGLT

研究领域 >> 代谢疾病

参考文献

[1]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701.

[2]. Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 Oct;170(3):519-31.

[3]. Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobioti

[4]. Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23.

分子式	C₂₂H₂₈O₇
分子量	404.45400
精确质量	404.18400
PSA	108.61000
LogP	0.93230
外观性状	粉末
储存条件	-20℃

CSG452

Tofogliflozin hydrate (JAN)

(1S,3'R,4'S,5'S,6'R)-6-((4-Ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)-spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol monohydrate

(1S,3'R,4'S,5'S,6'R)-6-((4-Ethylphenyl)methyl)-6'-(hydroxymethyl)-3',4',5',6'-tetrahydro-3H-spiro(2-benzofuran-1,2'-pyran)-3',4',5'-triol monohydrate

Tofogliflozin (USAN)

Tofogliflozin [USAN:INN]

UNII-P8DD8KX4O4

Tofogliflozin (hydrate)